A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Quadrants has released its latest Pharmacy Automation Startups/SMEs Companies Assessment, recognizing key players, including ...

The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay ...